superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.374
- Punti reazioni
- 1.105
Cvm
proviamo
proviamo
CVM - CEL-SCI Corporation (AMEX:CVM)
- Creatore Discussione superbaffone
- Data di inizio
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.374
- Punti reazioni
- 1.105
buona chiusura
ffaiper
nvediCOMEballaNASQAD
- Registrato
- 8/12/02
- Messaggi
- 1.583
- Punti reazioni
- 6
baffo,,,ottima ripresa della rialzista da parte di cvm,,,,se si conferma sopra 1,13 ,,,,lunedi puo essere interessante per il raggiungimento di 1,4,,,,,,,,,,,,,,,,in settimana la markero stretta
gli oscillatori sono invitanti,,,,,,,,,,,,,ilmovimento sembrerebbe di consolidamento sula trend,,e probabile inversione,,,,,,,,
gli oscillatori sono invitanti,,,,,,,,,,,,,ilmovimento sembrerebbe di consolidamento sula trend,,e probabile inversione,,,,,,,,
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.374
- Punti reazioni
- 1.105
...molto bene...
Ultima modifica:
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.374
- Punti reazioni
- 1.105
...forse riparte...
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.374
- Punti reazioni
- 1.105
Scritto da superbaffone
...forse riparte...
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.374
- Punti reazioni
- 1.105
VIENNA, Va., Dec 08, 2003 /PRNewswire-FirstCall via Comtex/ -- CEL-SCI CORPORATION (Amex: CVM) announces the following Webcast:
What: CEL-SCI Corporation News Conference
When: December 8, 2003 @ 11:00 a.m. EST
Where: http://www.videonewswire.com/event.asp?id=19208
How: Live over the Internet -- Simply log on to the web at the
address above.
Contact: Gavin de Windt (703) 506-9460
The webcast will discuss the science behind the new discovery that Multikine cancer immunotherapy may significantly increase the kill rate of cancer cells from radiation therapy.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.
What: CEL-SCI Corporation News Conference
When: December 8, 2003 @ 11:00 a.m. EST
Where: http://www.videonewswire.com/event.asp?id=19208
How: Live over the Internet -- Simply log on to the web at the
address above.
Contact: Gavin de Windt (703) 506-9460
The webcast will discuss the science behind the new discovery that Multikine cancer immunotherapy may significantly increase the kill rate of cancer cells from radiation therapy.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.
tremaui
KA MATE KA ORA!!
- Registrato
- 26/8/00
- Messaggi
- 2.325
- Punti reazioni
- 109
PRESS RELEASE: Study Demonstrates Multikine(R) Makes Tumor Cells Highly Suscepti [DCFZSBK]
VIENNA, Va., Dec. 8 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM)
announced the publication of data from a Phase I/II clinical trial in fifty-four
(54) advanced primary head and neck cancer patients. The data demonstrates that
treatment with CEL-SCI's immunotherapy drug Multikine(R) rendered the
overwhelming majority of the cancer cells highly susceptible to radiation
therapy. This finding represents a major advance in the treatment of cancer
since, under current standard therapy, only about 10% of the cancer cells are
thought to be susceptible to radiation therapy at any one point in time.
The data are published in The Laryngoscope, December 2003, Vol. 113 issue 12.
The title of the article is "The Effect of Leukocyte Interleukin Injection
(Multikine) on the Peritumoral and Intratumoral Subpopulation of Mononuclear
Cells and on Tumor Epithelia: A Possible New Approach to Augmenting Sensitivity
to Radiation Therapy and Chemotherapy in Oral Cancer -- A Multi Center Phase
I/II Clinical Trial." A copy of this article is available at
www.laryngoscope.com . The Laryngoscope, founded in 1896, is a leading medical
journal for head & neck cancer.
Dr. Eyal Talor, Senior Vice President of Research and Manufacturing at
CEL-SCI and the corresponding author of the study, said, "The findings of this
study may lead to a new approach for the treatment of many types of cancer. The
ability of Multikine to render a great majority of the cancer cells susceptible
to radiation when current radiation therapy can generally affect no more than
about 10% of cancer cells at any given treatment cycle, is a major breakthrough.
This discovery could increase by many-fold the "kill" rate of cancer cells with
radiation therapy, thus improving the effectiveness of cancer treatment."
Geert Kersten, CEO of CEL-SCI, added, "Treatment with Multikine results in an
anti-tumor immune response which reduces the number of cancer cells.
Subsequently, any remaining cancer cells are rendered much more susceptible to
radiation. All of this is achieved without toxicity. The study demonstrates
that Multikine may have the ability to transform how we treat cancer. To that
effect, it is our goal to launch a pivotal study with Multikine in advanced
primary head & neck cancer patients in combination with radiation therapy to
prove clinical benefit."
VIENNA, Va., Dec. 8 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM)
announced the publication of data from a Phase I/II clinical trial in fifty-four
(54) advanced primary head and neck cancer patients. The data demonstrates that
treatment with CEL-SCI's immunotherapy drug Multikine(R) rendered the
overwhelming majority of the cancer cells highly susceptible to radiation
therapy. This finding represents a major advance in the treatment of cancer
since, under current standard therapy, only about 10% of the cancer cells are
thought to be susceptible to radiation therapy at any one point in time.
The data are published in The Laryngoscope, December 2003, Vol. 113 issue 12.
The title of the article is "The Effect of Leukocyte Interleukin Injection
(Multikine) on the Peritumoral and Intratumoral Subpopulation of Mononuclear
Cells and on Tumor Epithelia: A Possible New Approach to Augmenting Sensitivity
to Radiation Therapy and Chemotherapy in Oral Cancer -- A Multi Center Phase
I/II Clinical Trial." A copy of this article is available at
www.laryngoscope.com . The Laryngoscope, founded in 1896, is a leading medical
journal for head & neck cancer.
Dr. Eyal Talor, Senior Vice President of Research and Manufacturing at
CEL-SCI and the corresponding author of the study, said, "The findings of this
study may lead to a new approach for the treatment of many types of cancer. The
ability of Multikine to render a great majority of the cancer cells susceptible
to radiation when current radiation therapy can generally affect no more than
about 10% of cancer cells at any given treatment cycle, is a major breakthrough.
This discovery could increase by many-fold the "kill" rate of cancer cells with
radiation therapy, thus improving the effectiveness of cancer treatment."
Geert Kersten, CEO of CEL-SCI, added, "Treatment with Multikine results in an
anti-tumor immune response which reduces the number of cancer cells.
Subsequently, any remaining cancer cells are rendered much more susceptible to
radiation. All of this is achieved without toxicity. The study demonstrates
that Multikine may have the ability to transform how we treat cancer. To that
effect, it is our goal to launch a pivotal study with Multikine in advanced
primary head & neck cancer patients in combination with radiation therapy to
prove clinical benefit."
Trasparente
Nuovo Utente
- Registrato
- 17/9/03
- Messaggi
- 110.202
- Punti reazioni
- 1.760
Premetto che non conosco il titolo ma ad occhio e croce mi sembra proprio che voglia andare a chiudere il gap. ciao.
PS ..e potrebbe essere una buona occasione per valutare la tenuta ed il comportamento.
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.374
- Punti reazioni
- 1.105
...si divertono i ragazzi...
superbaffone
1000k
- Registrato
- 23/7/03
- Messaggi
- 11.374
- Punti reazioni
- 1.105
VIENNA, Va., Dec 09, 2003 /PRNewswire-FirstCall via Comtex/ -- CEL-SCI CORPORATION (Amex: CVM) announces new data demonstrating that its CEL-1000 peptide was able to reduce a massive and overwhelming challenge dose of 50,000 sporozoites (malaria causing agent) in animals by a factor of 400 (from 100% down to 0.25%), as measured by the level of parasite mRNA detected in the liver 42 hours after challenge. The challenge amount used in these sets of experiments is 500 times higher than that used in the protection studies in which CEL-1000 was shown to protect 100% of the animals against malaria infection. The data were presented this past weekend by Dr. Yupin Charoenvit of the Naval Medical Research Center (NMRC) at the American Society of Tropical Medicine and Hygiene 2003 meeting in Philadelphia, PA.
The scientists also elucidated a key ingredient of the mechanism of action of CEL-1000. They showed that pre-treating the animals with a monoclonal antibody designed to block the cytokine IFN-g abolished protection. Pre- treatment with monoclonal antibodies against CD4 positive cells partially reduced protection. These findings show that protection with CEL-1000 is dependent on IFN-g and partially dependent on CD4 positive cells.
This report on CEL-1000 follows several grants for CEL-1000 in 2003. In April 2003, a $1.1 million grant that was awarded to develop CEL-1000 as a treatment for viral encephalitis, which includes West Nile Virus and three other viruses that the U.S. government has put into its listing as possible bio-terrorism agents. Two Phase I SBIR grants for CEL-1000 with application against vaccinia (September 2003) and Herpes (May 2003) were also awarded. In addition, in June 2003 CEL-SCI signed a Cooperative Agreement with the NIAID and the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) to test CEL-1000 against various bio-terrorism agents as well as other hard to treat diseases.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2002. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
The scientists also elucidated a key ingredient of the mechanism of action of CEL-1000. They showed that pre-treating the animals with a monoclonal antibody designed to block the cytokine IFN-g abolished protection. Pre- treatment with monoclonal antibodies against CD4 positive cells partially reduced protection. These findings show that protection with CEL-1000 is dependent on IFN-g and partially dependent on CD4 positive cells.
This report on CEL-1000 follows several grants for CEL-1000 in 2003. In April 2003, a $1.1 million grant that was awarded to develop CEL-1000 as a treatment for viral encephalitis, which includes West Nile Virus and three other viruses that the U.S. government has put into its listing as possible bio-terrorism agents. Two Phase I SBIR grants for CEL-1000 with application against vaccinia (September 2003) and Herpes (May 2003) were also awarded. In addition, in June 2003 CEL-SCI signed a Cooperative Agreement with the NIAID and the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) to test CEL-1000 against various bio-terrorism agents as well as other hard to treat diseases.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2002. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.